Fintech▲ 60

SeaStar Medical presents positive registry data

Globenewswire·March 30, 2026 at 12:20 PM

SeaStar Medical has showcased new positive data from its QUELIMMUNE SAVE Registry, focusing on pediatric patients. The results indicate no device-related adverse events or immunosuppression, alongside continued strong survival data. An analysis of the SCD therapy's unique immunomodulatory mechanism was also presented at AKI & CRRT 2026, suggesting promising outcomes for the treatment.

SeaStar Medical presents positive registry data

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing